CoChat
Sign Up
Cited by 57Multiple Sclerosis Research StudiesPolyomavirus and related diseasesPsoriasis: Treatment and Pathogenesis

The DOI matches its Crossref record.

Multiple sclerosis in Japan appears to be a milder disease compared to the UK

Piccolo, L., Kumar, G., Nakashima, I., Misu, T., Kong, Y., Wakerley, B., Ryan, S., Cavey, A., Fujihara, K., Palace, Jacqueline·2015·Journal of Neurology
DOI 10.1007/s00415-015-7637-3
Open this paper in CoChat — free account

Abstract

Multiple sclerosis (MS) is relatively common in the West, but rare in Japan. In the literature, there are few comparative data regarding disease severity throughout the world. The objective of this study was to compare disability in patients from a UK and a Japanese MS cohort. We retrospectively analysed the clinical features of patients with MS from a UK and Japanese MS centre. The Multiple Sclerosis Severity Score (MSSS), which adjusts the Expanded Disability Status Scale score according to disease duration, was used as a marker of disease severity. One thousand one hundred forty-eight UK patients and 104 Japanese patient were identified representing the relative national prevalence. Demographics and disease duration did not differ between the groups. Median MSSS was significantly different between the two groups (Japan 3.34 vs. UK 5.87, p < 0.001). Primary progressive MS was more common in the UK (12.9%) than in the Japanese cohort (3%, p = 0.044). The majority of Japanese patients (83.7% vs. UK 17%) had been exposed to disease modifying treatments (DMTs). Exposure to DMTs did not show a significant effect on disability. In conclusion, this study suggests that MS in Japan may be associated with less disability than in UK. More Japanese patients were treated with DMTs. Differences in treatments do not seem to explain the disparity in disability severity. This suggests either genetic or environmental influences on disease severity.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00415-015-7637-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28(1):17–28 · DOI
  2. Wang H, Munger KL, Reindl M et al (2008) Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 71(15):1142–1146 · DOI
  3. Faridar A, Eskandari G, Sahraian MA et al (2012) Vitamin D and multiple sclerosis: a critical review and recommendations on treatment. Acta Neurol Belg 112(4):327–333 · DOI
  4. Levin LI, Munger KL, O’Reilly EJ et al (2010) Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 67(6):824–830 · DOI
  5. Alonso A, Hernán MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71(2):129–135 · DOI
  6. Koutsouraki E, Costa V, Baloyannis S (2010) Epidemiology of multiple sclerosis in Europe: a review. Int Rev Psychiatry 22(1):2–13 · DOI
  7. Kira J (2003) Multiple sclerosis in the Japanese population. Lancet Neurol 2(2):117–127 · DOI
  8. Wasay M, Khatri IA, Khealani B, Sheerani M (2006) MS in Asian countries. Int MS J 13(2):58–65
  9. Houzen H, Niino M, Kikuchi S et al (2003) The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 211(1–2):49–53 · DOI
  10. Detels R, Visscher BR, Malmgren RM et al (1977) Evidence for lower susceptibility to multiple sclerosis in Japanese-Americans. Am J Epidemiol 105(4):303–310 · DOI
  11. Nakashima I, Fujihara K, Okita N et al (1999) Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 67(2):153–157 · DOI
  12. Osoegawa M, Kira J, Fukazawa T et al (2009) Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 15(2):159–173 · DOI
  13. Houzen H, Niino M, Hirotani M et al (2012) Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 323(1–2):117–122 · DOI
  14. Chong HT, Tan CT (2008) A review of multiple sclerosis with Asian perspective. Med J Malaysia 63(5):356–361
  15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–231 · DOI · Paper page
  16. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452 · DOI · Paper page
  17. Strange RC, Ramachandran S, Zeegers MP et al (2010) The Multiple Sclerosis Severity Score: associations with MC1R single nucleotide polymorphisms and host response to ultraviolet radiation. Mult Scler 16(9):1109–1116 · DOI
  18. Pachner AR, Steiner I (2009) The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci 278(1–2):66–70 · DOI
  19. Tanaka K, Kujuro Y, Suzuki S et al (2005) Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988–2002. Intern Med 44(6):560–566 · DOI
  20. Chan KH, Tsang KL, Ho PW et al (2011) Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese. Clin Neurol Neurosurg 113(8):617–622 · DOI
  21. Lau KK, Wong WW, Sheng B et al (2008) The clinical course of multiple sclerosis patients in Hong Kong. J Neurol Sci 268(1–2):78–82
  22. Chang KH, Lyu RK, Chen CM et al (2006) Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study. Mult Scler 12(4):501–506 · DOI
  23. Matsuoka T, Matsushita T, Kawano Y et al (2007) Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130(Pt 5):1206–1223 · DOI
  24. Gale CR, Martyn CN (1995) Migrant studies in multiple sclerosis. Prog Neurobiol 47(4–5):425–448 · DOI
  25. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64(7):1144–1151 · DOI · Paper page
  26. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, Takai Y, Takahashi T, Misu T, Elsone L, Woodhall M, George J, Boggild M, Vincent A, Jacob A, Fujihara K, Palace J (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 135(Pt 6):1834–1849 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Piccolo, L., Kumar, G., Nakashima, I., Misu, T., Kong, Y., Wakerley, B., Ryan, S., Cavey, A., Fujihara, K., & Palace, J.
Affiliations
  • University of Pavia (IT)
  • University of Oxford (GB)
  • Tohoku University (JP)
Corresponding author
Palace, Jacqueline
ORCID
Venue
Journal of Neurology
Publisher
Springer Science and Business Media LLC
Published
2015-01-22
Volume
262
Issue
4
Pages
831-836
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
DOI
10.1007/s00415-015-7637-3
OpenAlex
W2091211345
Cited by
57
References
0
Citations by year
2026: 2 · 2025: 1 · 2024: 13 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 2
FWCI
3.97
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ministère de la Santé et des Services sociaux
  • Japan Society for the Promotion of Science (22229008)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
multiple sclerosis, disease severity, disability, Multiple Sclerosis Severity Score, Expanded Disability Status Scale, primary progressive multiple sclerosis, disease-modifying therapy, cross-national comparison, Japan, United Kingdom, genetic and environmental risk factors
MeSH terms
Adult, Female, United Kingdom, Humans, Japan, Male, Middle Aged, Multiple Sclerosis, Severity of Illness Index, Cohort Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review